The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients
Abstract
CONTEXT: Adrenocortical carcinomas (ACC) are rare tumors with a poor prognosis. Few reports concerning large and homogeneous series are available. OBJECTIVE: We aimed to determine the clinical characteristics and outcome of ACC and to identify prognostic factors. DESIGN AND SETTING: This study is a descriptive and multivariate analysis of a cohort from a single endocrinology center. PATIENTS: A total of 202 consecutive patients with ACC were studied. RESULTS: The sex ratio (female to male) was 2.7. Mean age at diagnosis was 44 +/- 16 yr (range, 11-88 yr). We found that 154 patients (76%) had hypersecreting tumors [mostly cortisol and androgens (47%), cortisol alone (27%), or androgens alone (6%)] and 43 patients (21%) had metastases at diagnosis. At initial staging or during follow-up, 85 patients (42%) had liver metastases, 79 patients (39%) had lung metastases, and 20 patients had bone metastases (10%). The survival rate was 37% at 5 yr. Multivariate analysis identified the following independent prognostic factors associated with shorter survival: older age at diagnosis [hazard ratio (HR), 1.03; P < 0.0001], initial MacFarlane extension stages 3 (HR, 4.42; P = 0.005) and 4 (HR, 7.93; P < 0.0001), and cortisol hypersecretion (HR, 3.90; P < 0.0001). Treatment with 1,1-dichlorodiphenildichloroethane (o,p'DDD) in the 3 months after surgery increased the survival rate of patients with cortisol-secreting tumors (HR, 0.40; P = 0.04). CONCLUSION: This study highlights the better prognosis of ACC diagnosed at a noninvasive local stage, the particularly poor prognosis of patients with cortisol-secreting tumors, and the beneficial effect of o,p'DDD therapy in this subgroup of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The impact of the functional status and clinical features of ACCs on survival is unclear (132,133).”
From Adrenal incidentaloma (2020) · cites this paper as [133]
In the citing paper
“Biochemically or clinically apparent adrenocortical hormone production is evident in up to 45% to 70% (9, 10, 85).”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
In the citing paper
“Autonomous aldosterone secretion (which classically leads to hypertension and hypokalemia) is rare in ACC (85, 86).”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
In the citing paper
“At the time of presentation, ACCs are generally large tumors, measuring on average 10 to 13 cm (9, 85, 89).”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
In the citing paper
“Hypercortisolism is the most common presentation of patients presenting with hormone excess (50%–80% of hormone-secreting ACCs), causing classic symptoms including plethora, diabetes mellitus, muscle weakness/atrophy, and osteoporosis.”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
In the citing paper
“some recent studies identified cortisol production as an adverse prognostic factor (12, 85, 244).”
From Adrenocortical carcinoma (2014) · cites this paper as [85]
Citations
Cites
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10 · Cited by 2,097
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt‐Rasmussen, U., Hagen, C., Jørgensen, J. O. L., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 763
Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474
Self-citationBerruti, A., Terzolo, M., Sperone, P., Pia, A. R., Casa, S. D., Gross, D. J., Carnaghi, C., Casali, P. G., Porpiglia, F., Mantero, F., et al. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01025 · Cited by 308
Gicquel, C., BERTAGNA, X. Y., Gaston, V., Coste, J., Louvel, A., Baudin, É., Bertherat, J. Y., Chapuis, Y., Duclos, J. M., Schlumberger, M. J., et al. (2001) · PubMed · Cited by 285
Self-citationHutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90219-1 · Cited by 277
Hutter, A. M., & Kayhoe, D. E. (1966) · The American Journal of Medicine · doi:10.1016/0002-9343(66)90220-8 · Cited by 271
Macfarlane, D. A. (1958) · PubMed · Cited by 266
Sullan, M., Boileau, M. A., & Hodges, C. V. (1978) · The Journal of Urology · doi:10.1016/s0022-5347(17)57317-6 · Cited by 255
Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patients
Didolkar, M. S., Bescher, R. A., Elias, E. G., & Moore, R. H. (1981) · Cancer · doi:10.1002/1097-0142(19810501)47:9 · Cited by 243
Management of adrenocortical carcinoma
Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214
van Slooten, H., Moolenaar, A. J., van Seter, A. P., & Smeenk, D. (1984) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(84)90033-6 · Cited by 198
Molecular genetics of adrenocortical tumours, from familial to sporadic diseases
Libé, R., & Bertherat, J. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02004 · Cited by 168
Self-citationBukowski, R. M., Wolfe, M., Levine, H. S., Crawford, D., Stephens, R. L., Gaynor, E. R., & Harker, W. G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.161 · Cited by 110
Bertherat, J. Y., Contesse, V., Louiset, E., Barrande, G., Duparc, C., Groussin, L., Émy, P., BERTAGNA, X. Y., Kuhn, J., Vaudry, H., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1256 · Cited by 108
Self-citationAdrenal cortical carcinoma in Norway, 1970–1984
Søreide, J. A., Brabrand, K., & Thoresen, S. (1992) · World Journal of Surgery · doi:10.1007/bf02067349 · Cited by 101
Radiation therapy of adrenal cortical carcinoma
Percarpio, B., & Knowlton, A. H. (1976) · Acta Radiologica Therapy Physics Biology · doi:10.3109/02841867609131965 · Cited by 89
Luton, J., Martinez, M., Coste, J., & Bertherat, J. Y. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430111 · Cited by 70
Self-citationRadiation therapy for adjunctive treatment of adrenal cortical carcinoma
Markoe, A. M., Serber, W., Micaily, B., & Brady, L. W. (1991) · American Journal of Clinical Oncology · doi:10.1097/00000421-199104000-00015 · Cited by 69
[Cancer of the adrenal cortex].
Uspenskiĭ, L. V., Kurguzov, O. P., Savchenko, A. P., Lapchinskiĭ, V. A., & Denisova, O. P. (1980) · PubMed · Cited by 61
Lindhe, Ö., Skogseid, B. M., & Brandt, I. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8281 · Cited by 60
Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma
Sørensen, J., Hirsch, F. R., Gazdar, A. F., & Olsen, J. E. (1993) · Cancer · doi:10.1002/1097-0142(19930515)71:10 · Cited by 51
Sallah, S., Wan, J. Y., Nguyen, N. P., Vos, P. W., & Sigounas, G. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 47
Favia, G., Lumachi, F., & D'Amico, D. F. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0024-5 · Cited by 32
Significance of chromosome 14 anomaly at band 14Q11 in Japanese patients with adult T-cell leukemia
Sadamori, N., Nishino, K., Kusano, M., Tomonaga, Y., Tagawa, M., Yao, E.-I., Sasagawa, I., Nakamura, H., & Ichimaru, M. (1986) · Cancer · doi:10.1002/1097-0142(19861115)58:10 · Cited by 31
Cisplatin-based treatment of adrenocortical carcinoma.
Hesketh, P. J., McCaffrey, R. P., Finkel, H. E., Ss, L., Griffing, G. T., & Melby, J. C. (1987) · PubMed · Cited by 26
Causeret, S., Monneuse, O., Mabrut, J., Berger, N., & Peix, J.-L. (2002) · Annales de Chirurgie · doi:10.1016/s0003-3944(02)00774-5 · Cited by 10
Venkatesh (1989) · doi:10.1002/1097-0142(19890801)64:3
King (1979) · doi:10.1002/1097-0142(197907)44:1
Wooten (1993) · doi:10.1002/1097-0142(19931201)72:11
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Kasperlik-Załuska (1995) · doi:10.1002/1097-0142(19950515)75:10
Flagged first, then by citations
Cited by
Sorted by citations
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Faßnacht, M., Dekkers, O. M., Else, T., Baudin, É., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assié, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 976
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874
Integrated genomic characterization of adrenocortical carcinoma
Assié, G., Letouzé, E., Fassnacht, M., Jouinot, A., Luscap, W., Barreau, O., Omeiri, H., Rodriguez, S., Perlemoine, K., René-Corail, F., et al. (2014) · Nature Genetics · doi:10.1038/ng.2953 · Cited by 732
Self-citation
Metadata
- Authors
- Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J.
- Affiliations
- Hôpital Cochin (FR)
- Centre National de la Recherche Scientifique (FR)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-07
- Volume
- 91
- Issue
- 7
- Pages
- 2650-2655
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2140991656
- Cited by
- 435
- References
- 34
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 14 · 2023: 23 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 23 · 2018: 33 · 2017: 17 · 2016: 23 · 2015: 32 · 2014: 31 · 2013: 21 · 2012: 18
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- adrenocortical carcinoma, prognosis, prognostic factors, survival, liver metastasis, lung metastasis, age at diagnosis, mitotane, adjuvant chemotherapy, androgen-secreting tumor
- MeSH terms
- Adrenal Cortex Neoplasms, Adult, Analysis of Variance, Androgens, Bone Neoplasms, Female, Humans, Hydrocortisone, Liver Neoplasms, Lung Neoplasms, Male, Middle Aged, Mitotane, Neoplasm Staging, Prognosis, Survival Rate, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
